The global non-Hodgkin’s lymphoma therapeutics market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The condition occurs when the body produces too many abnormal lymphocytes, a type of white blood cell. Its symptoms include belly pain, fever, swollen lymph nodes, and chest pain. It is a form of blood cancer that impacts white blood cells known as lymphocytes. The pivotal factors that are driving the market growth include an increase in the number of population base suffering from various cell lymphomas coupled with the rise in the R&D activities in the healthcare sector resulting in a favorable product pipeline. The global non-Hodgkin’s lymphoma therapeutics market is majorly driven by the growing number of clinical trials as well as the growing approvals by various governmental agencies.
A full report of Global Non-Hodgkin’s Lymphoma Therapeutics Market is available at:https://orionmarketreports.com/global-non-hodgkins-lymphoma-therapeutics-market/93939/
Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the US, accounting for about 4% of all cancers. As per the American Cancer Society’s estimates for non-Hodgkin lymphoma in 2022, about 80,470 people (44,120 males and 36,350 females) will be diagnosed with non-Hodgkin lymphoma. This includes both adults and children. About 20,250 people will die from this cancer (11,700 males and 8,550 females). As per the study published in Cancer Journal for Clinicians, in 2016, 3,320 new cases of mantle cell lymphoma (MCL) were diagnosed in the US. Approvals for various new drugs by federal agencies is expected to drive the global market. The global non-Hodgkin’s lymphoma therapeutics market is also driven by development of targeted therapy drugs with low toxicity in combination with approved drugs for the treatment of relapsed lymphoma cases.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2020
- Forecast period- 2022-2028
- Segment Covered-
- By Type of Therapy
- By Cell Type
- Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape: Teva Pharmaceutical Industries Ltd., AstraZeneca plc, and Bayer AG, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Non-Hodgkin’s Lymphoma Therapeutics Market Report by Segment
By Type of Therapy
- Chemotherapy
- Targeted Therapy
By Cell Type
- B-Cell Lymphoma
- T-Cell Lymphoma
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
